[News] Many FDA-approved cancer drugs might lack clinical benefit

New research shows that less than half of the randomised controlled trials (RCTs) that support the approval of anticancer drugs by the US Food and Drug Administration (FDA) reach the threshold for clinical benefit as defined by the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Source: The Lancet Oncology - December 21, 2017 Category: Cancer & Oncology Authors: Manjulika Das Tags: News Source Type: research